Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune cell subtype profiling in ovarian cancer microenvironment using full-spectrum flow cytometry and application to individualized therapy
ChiCTR2000036898Phase 2Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Oct 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab, paclitaxel and carboplatin in ovarian cancer (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Overall survival. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000036898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036898.